The European Association for the Study of Obesity (EASO) identifies a structural crisis it terms the 'Integration Paradox': GLP-1 receptor agonists and dual GIP/GLP-1 agonists like semaglutide and tirzepatide have demonstrated 15–22% body weight reductions in trials, yet European healthcare systems lack the workforce capacity, reimbursement infrastructure, and equitable access mechanisms to deploy these agents responsibly at scale. EASO's five-pillar framework — Right Patient, Right Care, Right Workforce, Right Data, and Right Access — attempts to operationalize what the clinical trial ecosystem has largely ignored: sustainable implementation.
This position statement arrives at a critical inflection point. Incretin therapies are arguably the most consequential metabolic intervention since bariatric surgery, yet their rollout risks replicating the inequity patterns seen with earlier obesity biologics — concentrated among affluent, well-insured populations while failing those with the highest cardiometabolic burden. The EASO framework's emphasis on harmonized monitoring and real-world pharmacovigilance is particularly important given emerging signals around muscle mass loss, GI tolerability, and post-discontinuation weight regain that controlled trials underrepresent.
As a position statement rather than primary data, this document carries the weight of consensus opinion, not causal evidence. Its practical value lies in setting policy benchmarks across 29 European health systems with divergent reimbursement models. For clinicians, the key takeaway is systemic: prescribing incretin therapies without multidisciplinary behavioral and nutritional support infrastructure may optimize short-term metrics while undermining long-term outcomes. Incremental in originality, but strategically significant for health-system planning.
